Ignite Creation Date:
2025-12-24 @ 11:40 PM
Ignite Modification Date:
2026-02-26 @ 6:52 AM
Study NCT ID:
NCT02588651
Status:
COMPLETED
Last Update Posted:
2025-11-21
First Post:
2015-10-26
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Sponsor:
Deepa Jagadeesh
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-06-17
Start Date Type:
ACTUAL
Primary Completion Date:
2024-10-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-10-14
Completion Date Type:
ACTUAL
First Submit Date:
2015-10-26
First Submit QC Date:
None
Study First Post Date:
2015-10-28
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2025-10-13
Results First Submit QC Date:
None
Results First Post Date:
2025-11-21
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-10
Last Update Post Date:
2025-11-21
Last Update Post Date Type:
ESTIMATED